GlobeNewsWire
12 Feb 2026, 23:00 UTC · 31w ago
Verdict
Headline leans bullish. We score EBS +0.80 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA approved Emergent BioSolutions' supplemental New Drug Application for 6-count and 24-count multipack configurations of OTC NARCAN Nasal Spray.
More positive than 61% of claims this week
The new multipacks will be available for purchase through the company's proprietary distribution platform, NARCANdirect.
So whatDirect-to-customer distribution can improve margins by reducing reliance on third-party intermediaries.
Continue reading
5 related stories
More positive than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 39% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company received FDA approval for new multipack configurations of NARCAN, expanding its product suite and distribution capabilities.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−39.6%
Price is moving against the score
$6.55 vs $10.85 close before publication (Feb 12) · not market-adjusted
EBS chart →